Titre du document / Document title

Intravitreal bevacizumab (Avastin) in treatment of neovascular age-related macular degeneration

Auteur(s) / Author(s)

LAZIC Ratimir ; GABRIC Nikica ; DEKARIS Iva ; SARIC Borna ; GAVRIC Morena ;

Résumé / Abstract

To evaluate the efficacy and safety of intravitreal bevacizumab in treatment of minimally classic and occult choroidal neovascularization secondary to age-related macular disease 48 eyes of 48 patients (mean age of 74.8) included in this prospective, noncomparative, interventional case series. Median follow-up was 18 weeks (6-24). Intravitreal bevacizumab injection of 0.05 mL (1.25 mg) was administered at baseline and in 6 week intervals until leakage resolved, and repeated in case of leakage recurrence. Visual acuity (VA) improved in the majority of patients (mean baseline VA=1.078 log MAR) by mean increase of 1.32 lines (last follow-up) (p=0.001). Central foveal thickness and total macular volume decreased by 51 μm (p=0.01) and 0.84 mm³ (p<0.0001) respectively. No serious complications were observed. As initial therapy, intravitreal bevacizumab appears to be safe and effective. A significant functional and anatomical improvement was noted in majority of patients and maintained during follow-up.

Revue / Journal Title

Collegium antropologicum   ISSN 0350-6134 

Source / Source

2007, vol. 31, pp. 77-81, SUP1 [5 page(s) (article)]

Langue / Language

Anglais

Editeur / Publisher

Croatian Anthropological Society, Zaghreb, CROATIE  (1977) (Revue)

Mots-clés d'auteur / Author Keywords

bevacizumab ; ranibizumab ; pegaptanib ;

Localisation / Location

INIST-CNRS, Cote INIST : 26235, 35400014695549.0180